MyoVista Insights is a device-agnostic ECG management system that brings AI directly into the clinical workflow — vendor-neutral, cloud-native, Epic-integrated.
Epic TOOLBOX 2026
Powered by AWSTrusted by leading health systems & partners
MyoVista Insights is a device-agnostic, next-generation ECG management system. It centralizes ECG data from major manufacturers, surfaces critical findings, and runs FDA-cleared AI-ECG models — all in a single unified workflow.
Comprehensive cardiac screeningSurfaces left-ventricular dysfunction and structural abnormalities standard interpretation often misses.
Critical-finding prioritizationConfidence-scored alerts route the most urgent ECGs to the top of the worklist.
Seamless EHR integrationResults flow directly into Epic via the Epic TOOLBOX designation; HL7 FHIR for everyone else.
Vendor neutral
12-lead, any device
Cloud native
AWS infrastructure
EHR ready
Epic TOOLBOX 2026
23+
Peer-reviewed publications
JACC, Nature, JAHA, EHJ, npj Digital Medicine
15+
AI-ECG algorithms
Pre-FDA + in development
123
Hospitals on network
Cibolo Health, six U.S. states
Nasdaq
Public on HSCS
ISO 13485 certified · CE marked
Standard ECG interpretation has been largely unchanged for decades. Subtle, low-amplitude signals — the patterns AI is exceptional at — go unread.
Conventional 12-lead ECG focuses on rhythm and gross morphology. Early-stage cardiac dysfunction sits in the signal but stays invisible to the human eye.
Diastolic dysfunction undetectable on standard ECGCirculation, 2022
Low ejection fraction often missed until symptomaticEuropean Heart Journal, 2023
Echocardiography required for definitive diagnosis ($500–$2,000 per study)AHA cost reference, 2024
Partner AI-ECG algorithms — surfaced through MyoVista Insights — extract clinically meaningful signals from the standard ECG, flagging patients who may benefit from echocardiography before symptoms appear.
AI-ECG analysis identifies subclinical LV dysfunction in T2DM patientsCardiovascular Diabetology, 2024 — AUC 0.81
Quantitative prediction of right-ventricular size & function from a 12-lead ECGJAHA, 2024 — AUC 0.86
Works with 12-lead ECG devices from major manufacturersVendor-neutral by design
No new hardware. No new workflow. Standard 12-lead ECGs flow through Insights and back into the chart in seconds.
Standard 12-lead ECG from any major manufacturer — GE, Philips, Mortara, Cardioline, Welch Allyn, Baxter.
Multiple AI-ECG algorithms run in parallel through MyoVista Insights and return a structured report in seconds.
Critical findings rise to the top of the worklist; results flow back into Epic via the TOOLBOX 2026 designation.
Connect 12-lead devices from major manufacturers, deploy multiple AI algorithms on a single ECG, and pipe results straight into the Epic chart.
Connect 12-lead ECG devices from major manufacturers, including GE, Philips, Mortara, Cardioline, Welch Allyn, and Baxter. No hardware lock-in, no proprietary formats.
Deploy multiple AI algorithms on a single ECG, with status badging for FDA-cleared, Pre-FDA, and in-development models. Operators choose what fits their pathway.
Native HL7 FHIR R4. Epic TOOLBOX 2026 designation. Results flow into existing chart workflows without an adapter layer.
Built on AWS. Auto-scales from a single clinic to a multi-hospital health system. HIPAA-compliant infrastructure, audit logging on every record.
Each algorithm is validated through peer-reviewed research and routed through the same Insights workflow.
Detect reduced left-ventricular systolic function from a standard 12-lead ECG.
Identify HFpEF indicators in patients whose EF reads as preserved on echo.
Diastolic dysfunction screening — the first algorithm in the wavECG submission pathway.
Screen for valvular abnormalities historically requiring echocardiography.
Aortic valve disease detection in routine ECG recordings.
Acute PE risk stratification at the point of care.
Quantitative right-ventricular size and function prediction (JAHA, 2024).
Elevated ST-segment / MI detection (HeartBEiT vision-transformer family).
Predict cardiomyopathy risk in patients with premature ventricular complexes.
Partner AI-ECG algorithms available through MyoVista Insights are validated in leading medical journals — JACC, Nature Medicine, EHJ Digital Health, JAHA, and more.
Journal of the American Heart Association · 2024
npj Digital Medicine · 2023
Cardiovascular Diabetology · 2024
You've just solved the world's backlog problem.
Early adopter
Healthcare partner
You had me at hello, but you really, you REALLY had me with the comparisons.
Cardiology
Clinical partner
Our GPs love it. They are still salivating over the caliper tool.
Primary care director
Healthcare system
And I loved the filters. This is moving towards my ECG nirvana.
Cardiologist
Early adopter
I really like this. What burns me the most is not having complete control of the filters. This prevents 80-year-old patients from being dragged across town to redo the ECG.
Clinical user
Primary care
Regarding ECG overlays — this is awesome. I don't think anyone else has this feature.
Healthcare partner
Early adopter
There hasn't been a solution in the middle, between the AI-ECG and EHR, that pulls this all together. The other solutions are all standalone.
Healthcare IT director
Health system
Product launches, regulatory milestones, and clinical partnerships.
Cibolo Rural Health Networks has selected MyoVista Insights as its endorsed ECG management platform for the 123 independent hospitals across six states inside its high-value networks.
Read storyThe MyoVista wavECG device — a 12-lead ECG platform designed to host AI-ECG algorithms — has been submitted to the FDA for 510(k) premarket clearance.
Read storyVersion 1.1 ships a redesigned worklist, longitudinal ECG comparison overlays, and a faster waveform caliper — built around feedback from early-adopter clinicians.
Read storyWalk through the platform with our team and see how it fits the ECG management problem you're trying to solve.
